Moleculin Biotech price to book ratio MBRX

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: 0.5×
10-year median: 1.1×
Against its 10-year history: 23rd; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.1× to 191×
Peer median: 1.6×

Moleculin Biotech's price to book ratio is 0.5× as of Oct 23, 2026.

That is below its ten-year median of 1.1×, lower than on 77% of days in the last ten years.

Over that time it ranged from 0.1× in Jul 2026 to 191× in Jul 2025.

The median for 3 healthcare stocks of a similar size is 1.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.5×	0.1×	1.3×
2025	191×	0.3×	191×
2024	0.7×	0.2×	1.1×
2023	0.7×	0.3×	0.7×
2022	0.5×	0.4×	0.7×
2021	0.7×	0.7×	6.5×
2020	3.4×	1.1×	4.7×
2019	2.4×	1.6×	3.9×
2018	1.9×	1.8×	2.9×
2017	2.1×	0.8×	3.2×
2016	1.7×	1.2×	4.3×

Against its peers

Companies in Healthcare nearest Moleculin Biotech's size, closest first, today.

Company	Price to book ratio
MBRXMoleculin Biotech	0.5×
NEPHNephros	3.2×
ATNMActinium Pharmaceuticals	1.6×
APTAlpha Pro Tech	0.9×
Peer median	1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Moleculin Biotech

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.